1-(4-azidophenyl)-4-methylpiperazine | 1612887-87-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-azidophenyl)-4-methylpiperazine
• CAS: 1612887-87-2
• 化学式: C₁₁H₁₅N₅
• 分子量: 217.274
• InChiKey: VZFJMFLHVLBJOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  20.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-羟基-1,4-萘醌 、 1-(4-azidophenyl)-4-methylpiperazine 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 乙腈 为溶剂， 反应 12.0h， 生成 1-(4-(4-methylpiperazin-1-yl)phenyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
  参考文献：
  名称：

  Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO)

  摘要：

  Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), which mediate kynurenine pathway of tryptophan degradation, have emerged as potential new targets in immunotherapy for treatment of cancer because of their critical role in immunosuppression in the tumor microenvironment. In this investigation, we report the structural optimization and structure-activity relationship studies of 1-phenyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as a new class of IDO1/TDO dual inhibitors. Among all the obtained dual inhibitors, 1-(3-chloro-4-fluorophenyl)-6-fluoro-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (38) displayed the most potent IDO1 and TDO inhibitory activities with IC₅₀ (half-maximal inhibitory concentration) values of 5 nM for IDO1 and 4 nM for TDO. It turned out that compound 38 was not a PAINS compound. Compound 38 could efficiently inhibit the biofunction of IDO1 and TDO in intact cells. In LL2 (Lewis lung cancer) and Hepa1-6 (hepatic carcinoma) allograft mouse models, this compound also showed considerable in vivo anti-tumor activity and no obvious toxicity was observed. Therefore, 38 could be a good lead compound for cancer immunotherapy and deserving further investigation.

  DOI：

  10.1016/j.ejmech.2020.112703
• 作为产物：
  描述：

  在 sodium azide 作用下， 以 乙腈 为溶剂， 生成 1-(4-azidophenyl)-4-methylpiperazine
  参考文献：
  名称：

  Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO)

  摘要：

  Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), which mediate kynurenine pathway of tryptophan degradation, have emerged as potential new targets in immunotherapy for treatment of cancer because of their critical role in immunosuppression in the tumor microenvironment. In this investigation, we report the structural optimization and structure-activity relationship studies of 1-phenyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as a new class of IDO1/TDO dual inhibitors. Among all the obtained dual inhibitors, 1-(3-chloro-4-fluorophenyl)-6-fluoro-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (38) displayed the most potent IDO1 and TDO inhibitory activities with IC₅₀ (half-maximal inhibitory concentration) values of 5 nM for IDO1 and 4 nM for TDO. It turned out that compound 38 was not a PAINS compound. Compound 38 could efficiently inhibit the biofunction of IDO1 and TDO in intact cells. In LL2 (Lewis lung cancer) and Hepa1-6 (hepatic carcinoma) allograft mouse models, this compound also showed considerable in vivo anti-tumor activity and no obvious toxicity was observed. Therefore, 38 could be a good lead compound for cancer immunotherapy and deserving further investigation.

  DOI：

  10.1016/j.ejmech.2020.112703

文献信息

• RAFAMYCIN ANALOGS AND METHODS FOR MAKING SAME
  申请人：HANGZHOU ZYLOX PHARMA CO., LTD

  公开号：US20150051242A1

  公开（公告）日：2015-02-19

  A semi-synthetic rapamycin analog with a triazole moiety or a pharmaceutically acceptable salt or prodrug thereof, is a broad-spectrum cytostatic agent and a mTOR inhibitor, and is useful in the treatment of various cancers, or tumors in organs such as kidney, liver, breast, head and neck, lung, prostate, and restenosis in coronary arteries, peripheral arteries, and arteries in the brain, immune and autoimmune diseases. Also disclosed are fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosois, post-transplant tissue rejection, and immune and autoimmune disease in a mammal. One particular preferred application of such triazole-moiety containing rapamycin analog is in treating renal carcinoma, lung cancer, colon cancer, and breast cancers wherein potency of the drug, its half-life, tissue distribution properties, and its pharmacokinetic properties including bioavailability through oral and intravenous routes are essential to the clinical outcomes.

  一种含有三唑基团或其药用可接受盐或前药的半合成雷帕霉素类似物，是一种广谱细胞静止剂和 mTOR 抑制剂，可用于治疗各种癌症或器官肿瘤，如肾脏、肝脏、乳腺、头颈部、肺部、前列腺，以及冠状动脉、外周动脉和脑动脉的再狭窄，免疫和自身免疫疾病。还公开了抑制真菌生长、再狭窄、移植后组织排斥以及免疫和自身免疫疾病的组合物和在哺乳动物中抑制癌症、真菌生长、再狭窄、移植后组织排斥以及免疫和自身免疫疾病的方法。其中一种特定的首选应用是含有三唑基团的雷帕霉素类似物在治疗肾癌、肺癌、结肠癌和乳腺癌方面，药物的效力、半衰期、组织分布特性以及其药代动力学特性，包括口服和静脉途径的生物利用度对临床结果至关重要。
• [EN] RAPAMYCIN ANALOGS AND METHODS FOR MAKING SAME<br/>[FR] ANALOGUE DE LA RAPAMYCINE ET PROCÉDÉS DE FABRICATION ASSOCIÉS
  申请人：HANGZHOU ZYLOX PHARMA CO LTD

  公开号：WO2014082286A9

  公开（公告）日：2014-11-13
• Discovery of 8-(6-Methoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,5-dihydro-<i>4H</i>-[1,2,3]triazolo[4,5-<i>c</i>]quinolin-4-one (CQ211) as a Highly Potent and Selective RIOK2 Inhibitor
  作者：Yifan Ouyang、Hongfei Si、Chengjun Zhu、Liang Zhong、Haowen Ma、Zongyang Li、Huilan Xiong、Tongzheng Liu、Zhong Liu、Zhang Zhang、Zhi-Min Zhang、Qian Cai

  DOI：10.1021/acs.jmedchem.2c00271

  日期：2022.6.9

  in both enzymatic and cellular studies. It also exhibits potent proliferation inhibition activity against multiple cancer cell lines and demonstrates promising in vivo efficacy in mouse xenograft models. The crystal structure of RIOK2-CQ211 sheds light on the molecular mechanism of inhibition and informs the subsequent optimization. The study provides a cell-active chemical probe for verifying RIOK2